Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
This study has been completed.
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
First received: July 7, 2003
Last updated: June 27, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2005|
|Primary Completion Date:||July 2005 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wecker M, Gilbert P, Russell N, Hural J, Allen M, Pensiero M, Chulay J, Chiu YL, Abdool Karim SS, Burke DS; HVTN 040/059 Protocol Team.; NIAID HIV Vaccine Trials Network.. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol. 2012 Oct;19(10):1651-60.